The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy.
 
Ann H. Partridge
No Relationships to Disclose
 
Olivia Pagani
Consulting or Advisory Role - Novartis; Pfizer; Roche
Speakers' Bureau - Novartis; Pfizer; Roche
 
Hatem A. Azim
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - GlaxoSmithKline; IPS Genomics; NanoString Technologies
Speakers' Bureau - GlaxoSmithKline
Research Funding - Amgen; AstraZeneca (Inst); GlaxoSmithKline (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Novartis
 
Fedro Peccatori
No Relationships to Disclose
 
Monica Ruggeri
No Relationships to Disclose
 
Meredith M. Regan
Consulting or Advisory Role - Ipsen (Inst); Merck
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ferring (Inst); Ipsen (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); OncoGenex (Inst); Pfizer (Inst); Pierre Fabre (Inst); Veridex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Richard D. Gelber
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Zhuoxin Sun
No Relationships to Disclose